Literature DB >> 29160144

Parkinson's disease psychosis: presentation, diagnosis and management.

Ruth B Schneider1, Julia Iourinets2, Irene H Richard2.   

Abstract

Parkinson's disease is a neurodegenerative disorder characterized by motor and nonmotor symptoms. Psychosis is a common feature of Parkinson's disease. Parkinson's disease psychosis (PDP) encompasses minor phenomena (illusions, passage hallucinations and presence hallucinations), visual and nonvisual hallucinations and delusions. PDP is associated with reduced function and quality of life. The initial management approach should focus on identification and treatment of any contributory medical factors, reduction or discontinuation of medications with potential to induce or worsen psychosis, nonpharmacological strategies and consideration of acetylcholinesterase inhibitor treatment in the setting of dementia. Pimavanserin, quetiapine and clozapine may all be considered for use in PDP. In this review, we discuss the presentation, diagnosis and management of PDP.

Entities:  

Keywords:  Parkinson's disease; antipsychotic; delusions; hallucinations; pimavanserin; psychosis

Mesh:

Substances:

Year:  2017        PMID: 29160144     DOI: 10.2217/nmt-2017-0028

Source DB:  PubMed          Journal:  Neurodegener Dis Manag        ISSN: 1758-2024


  27 in total

1.  Chlorpyrifos Exposure Induces Parkinsonian Symptoms and Associated Bone Loss in Adult Swiss Albino Mice.

Authors:  Shaheen Jafri Ali; Govindraj Ellur; Kalpana Patel; Kunal Sharan
Journal:  Neurotox Res       Date:  2019-07-31       Impact factor: 3.911

2.  Downregulation of lncRNA BACE1-AS improves dopamine-dependent oxidative stress in rats with Parkinson's disease by upregulating microRNA-34b-5p and downregulating BACE1.

Authors:  Yanhong Li; Jian Fang; Zhanye Zhou; Qiyu Zhou; Shibin Sun; Zhikai Jin; Ziming Xi; Jianshe Wei
Journal:  Cell Cycle       Date:  2020-04-19       Impact factor: 4.534

3.  Neuropsychiatric Manifestations of Wilson Disease: Correlation with MRI and Glutamate Excitotoxicity.

Authors:  Jayantee Kalita; Vijay Kumar; Vasudev Parashar; Usha K Misra
Journal:  Mol Neurobiol       Date:  2021-08-26       Impact factor: 5.590

Review 4.  Sex Differences in the Gut-Brain Axis: Implications for Mental Health.

Authors:  Calliope Holingue; Alexa Curhan Budavari; Katrina M Rodriguez; Corina R Zisman; Grace Windheim; M Daniele Fallin
Journal:  Curr Psychiatry Rep       Date:  2020-11-20       Impact factor: 5.285

5.  The influences of behavioral and psychological interventions on the neurological function and MMSE scores in Parkinson's disease patients.

Authors:  Aimin Luo; Shuming Zhong; Shunkai Lai; Yanbin Jia
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

Review 6.  NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential.

Authors:  Na Xie; Lu Zhang; Wei Gao; Canhua Huang; Peter Ernst Huber; Xiaobo Zhou; Changlong Li; Guobo Shen; Bingwen Zou
Journal:  Signal Transduct Target Ther       Date:  2020-10-07

7.  Symptom burden among individuals with Parkinson disease: A national survey.

Authors:  Christopher G Tarolli; Grace A Zimmerman; Peggy Auinger; Scott McIntosh; Robert K Horowitz; Benzi M Kluger; E Ray Dorsey; Robert G Holloway
Journal:  Neurol Clin Pract       Date:  2019-11-18

8.  Icariside II promotes the differentiation of human amniotic mesenchymal stem cells into dopaminergic neuron-like cells.

Authors:  Wei Kuang; Tao Liu; Fang He; Limei Yu; Qian Wang; Changyin Yu
Journal:  In Vitro Cell Dev Biol Anim       Date:  2021-03-15       Impact factor: 2.416

Review 9.  The Combination of Tradition and Future: Data-Driven Natural-Product-Based Treatments for Parkinson's Disease.

Authors:  Zhijun Miao; Jinwei Bai; Li Shen; Rajeev K Singla
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-14       Impact factor: 2.629

10.  miR-101-3p Contributes to α-Synuclein Aggregation in Neural Cells through the miR-101-3p/SKP1/PLK2 Pathway.

Authors:  Min Zhang; Wei Liu; Qingan Zhang; Hongfeng Hu
Journal:  J Healthc Eng       Date:  2021-06-12       Impact factor: 2.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.